No connection

Search Results

ARQT vs PRVA

ARQT
Arcutis Biotherapeutics, Inc.
BEARISH
Price
$22.75
Market Cap
$2.82B
Sector
Healthcare
AI Confidence
85%
PRVA
Privia Health Group, Inc.
NEUTRAL
Price
$24.02
Market Cap
$3.02B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ARQT
--
PRVA
126.42
Forward P/E
ARQT
17.79
PRVA
20.08
P/B Ratio
ARQT
14.81
PRVA
4.03
P/S Ratio
ARQT
7.5
PRVA
1.42
EV/EBITDA
ARQT
-359.13
PRVA
57.87

Profitability

Gross Margin
ARQT
90.24%
PRVA
9.87%
Operating Margin
ARQT
14.2%
PRVA
2.08%
Profit Margin
ARQT
-4.29%
PRVA
1.08%
ROE
ARQT
-9.3%
PRVA
4.03%
ROA
ARQT
-1.96%
PRVA
1.71%

Growth

Revenue Growth
ARQT
81.5%
PRVA
17.4%
Earnings Growth
ARQT
--
PRVA
132.8%

Financial Health

Debt/Equity
ARQT
0.6
PRVA
0.01
Current Ratio
ARQT
3.17
PRVA
1.6
Quick Ratio
ARQT
2.83
PRVA
1.55

Dividends

Dividend Yield
ARQT
--
PRVA
--
Payout Ratio
ARQT
0.0%
PRVA
0.0%

AI Verdict

ARQT BEARISH

ARQT's Piotroski F-Score of 1/9 indicates severe financial distress, with weak profitability, negative ROE and ROA, and no dividend, signaling poor operational health. Despite strong revenue growth of 81.5% YoY and a forward P/E of 17.79, the company remains unprofitable with a negative profit margin of -4.29% and no intrinsic value or Graham Number available. Insider selling totaling $5.12M in the last six months, including significant sales by the CEO and directors, reinforces bearish sentiment. The stock trades at a premium to its fundamentals, with a Price/Sales of 7.50 and Price/Book of 14.81, suggesting overvaluation relative to earnings and book value. Analysts' strong_buy consensus appears disconnected from the underlying financial deterioration.

Strengths
81.5% YoY revenue growth indicates strong market expansion and product demand
High gross margin of 90.24% reflects efficient production and pricing power
Strong current and quick ratios (3.17 and 2.83) suggest solid short-term liquidity
Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and operational instability
Negative ROE (-9.30%) and ROA (-1.96%) indicate poor capital efficiency and unprofitability
Insider selling of $5.12M in 6 months, including CEO and directors, raises governance concerns
PRVA NEUTRAL

PRVA presents a stark contrast between fundamental value and growth expectations, anchored by a stable Piotroski F-Score of 4/9. While the company maintains an exceptionally clean balance sheet with near-zero debt, it trades at a massive premium compared to its Graham Number ($5.05) and Intrinsic Value ($5.61). Strong analyst conviction and impressive YoY earnings growth are currently offset by aggressive insider selling from the CEO and CFO and razor-thin profit margins. The stock is essentially a high-growth bet where the market is pricing in future earnings far beyond current deterministic valuations.

Strengths
Exceptionally low Debt/Equity ratio (0.01), indicating minimal financial leverage risk
Strong revenue growth (17.40% YoY) and explosive annual earnings growth (132.80%)
Consistent track record of beating earnings estimates (3 of last 4 quarters)
Risks
Extreme valuation gap: Current price ($24.02) is >4x the Graham Number ($5.05)
Very thin profitability margins (Profit Margin: 1.08%, Gross Margin: 9.87%)
Bearish insider sentiment with significant selling by the CEO and CFO

Compare Another Pair

ARQT vs PRVA: Head-to-Head Comparison

This page compares Arcutis Biotherapeutics, Inc. (ARQT) and Privia Health Group, Inc. (PRVA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile